echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Hydroxychloroquine protects against placental injury in obstetric antiphospholipid syndrome

    Hydroxychloroquine protects against placental injury in obstetric antiphospholipid syndrome

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Obstetric antiphospholipid syndrome (OAPS) is mediated by antiphospholipid antibodies (aPLs, anti-β2 glycoprotein I antibody is the main causative antibody), and placental diseases such as recurrent miscarriage, pre-eclampsia, and fetal growth restriction are the main clinical features
    of placental pathological pregnancy.
    It is a disease
    that seriously threatens the health of pregnant women.
    Originally used as an antimalarial agent, hydroxychloroquine (HCQ) now shows benefit in refractory OAPS where conventional treatment has failed, promising protective clinical benefits
    for both mother and fetus.

    HCQ has been shown to reduce aPLs titers in plasma
    in primary or secondary antiphospholipid syndromes.
    Prenatal exposure to HCQ in anti-SSA/SSB seropositive patients reduces the risk of
    fetal cardiac manifestations in neonatal lupus.

    However, its efficacy and mechanism of action are unclear
    Therefore, the investigators systematically evaluated the effects of anti-β2GP1 antibodies on trophoblast cell function and investigated the effects of
    HCQ in vivo and in vitro.
    To determine whether HCQ can reverse adverse effects of antibodies on multiple trophoblast functions and whether HCQ plays a key role
    in the pathogenesis of adverse pregnancy and fetal outcomes.

    OAPS placental pattern diagram for HCQ-treated:

    Therapeutic effects of HCQ in APS animal models:

    After collecting clinical data to determine the therapeutic effect, human trophoblast cells in the first trimester of pregnancy were prepared and treated
    with aPL.
    After HCQ addition, the proliferation, invasion, migration and tubule formation of trophoblast cells were observed to determine the therapeutic mechanism
    of HCQ on trophoblast cells.
    By establishing a mouse model of obstetric APS similar to the clinical situation, the therapeutic effect
    of HCQ on pathological pregnancy can be tested.
    The normal function of trophoblast cells is affected
    by aPL.
    Antibodies reduce the ability of trophoblast cells to invade and migrate and may impair tubule formation, which is closely related to
    placental insufficiency.
    HCQ can partially reverse these side effects
    In an OAPS mouse model, the researchers found that HCQ prevented fetal death and reduced the incidence
    of pathological pregnancies.

    Thus, HCQ can improve pregnancy outcomes and reverse aPL inhibition
    of trophoblast disease.
    In OAPS, the use of
    HCQ needs to be carefully considered.
    The mechanism of HCQ can provide new ideas and treatment options
    for placental diseases caused by immune dysfunction.

    HCQ reduces fetal absorption and placental abnormalities in OAPS:


    Liu J, Zhang L, Tian Y, Wan S, Hu M, Song S, Zhang M, Zhou Q, Xia Y, Wang X.
    Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome.
    J Cell Mol Med.
    2022 Aug; 26(15):4357-4370.
    doi: 10.
    Epub 2022 Jun 29.
    PMID: 35770338; PMCID: PMC9344817.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.